Monoclonal antibody · developed by ProMis Neurosciences
PMN310 is a humanized immunoglobulin G1 (IgG1) monoclonal antibody. It is studied in early-onset Alzheimer disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06750432 | Phase 1 | Alzheimer Disease, Early Onset | Active not recruiting | PMN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alzheimer Disease, Early Onset
Updated Oct 25, 2026. Something wrong or missing? Report it on the PMN page.
See PMN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PMN catalysts and pipeline →